To provide the information your oncologist is not telling you or doesn't have the time to!
Unleash the power of your body’s immune system in the fight against cancer with our “Immunotherapy” subcategory. Delve into the realm of groundbreaking treatments that empower your immune system to recognize and combat cancer cells. Explore the latest advances in immunotherapy, from checkpoint inhibitors to CAR-T cell therapies, and learn how they are revolutionizing the landscape of cancer treatment. Join us on a journey to understand how harnessing your body’s natural defenses is paving the way for more targeted and effective therapies in the fight against cancer.
A Promising New Treatment for Metastatic Breast Cancer: Exploring Bria-IMT™ and Its Impact When battling metastatic breast cancer, finding effective treatment options can feel like an uphill battle, especially when cancer has spread to other areas, like the brain. But new hope is on the horizon. A groundbreaking therapy called Bria-IMT™ is showing promising results in clinical …
October is Breast Cancer Awareness Month, a time dedicated to spreading knowledge, supporting research, and empowering patients and healthcare providers alike. Throughout the month, we’ll explore various critical aspects of breast cancer care. In this post, we focus on the current role of immunotherapy in treatment and encourage both patients and providers to consider clinical …
When I meet new patients diagnosed with Stage IV metastatic melanoma, I often mention the name Jimmy Carter. It’s a name most people recognize, and his survival story is nothing short of remarkable—especially considering he will soon celebrate his 100th birthday. Like many of my patients, Carter was diagnosed with Stage IV melanoma, with metastatic …
The American Society of Clinical Oncology (ASCO) 2024 conference was a remarkable event, bringing together leading minds in oncology to discuss the latest breakthroughs and research in cancer treatment. This year’s conference was particularly notable for the innovative approaches presented in the treatment of metastatic melanoma, a challenging and aggressive form of skin cancer. In …
The medical community continues to explore groundbreaking treatments in the fight against cancer, with CAR-T therapy standing out for its innovative approach. This treatment, involving the genetic modification of a patient’s T cells to target cancer cells, has provided new avenues for those battling certain blood cancers. Here, we delve into the essence of CAR-T …
Last week, we heard the tremendous news regarding the FDA approval of Lifileucel for metastatic melanoma refractory to prior immunotherapy checkpoint inhibitor therapy. In this article, let’s focus on an uncommon melanoma subtype in the general population that we routinely see in practice. In the realm of oncology, the fight against cancer continually evolves, marked …
On February 16th 2024, after a roughly 2-3 year wait fully aware of the data and the patient beneficial long term outcomes in a subset of patients, the FDA finally announced the approval of the first cellular therapy approved for solid tumors and specifically TIL in treatment refractory malignant melanoma. TIL using Amtagvi (Lifileucel) is …
This is a new modified TIL protocol developed by Obsidian Therapeutics now open for enrollment at the Orlando Health Cancer Institute. All information provided here are from public sources and the protocol details can be found here. Please reach out to Karin Donaldson if interest in seeking this trial. This current protocol is specific for …
This post is based on the interesting results published by Routy et al. Nature July 2023. I am hoping that we will soon open a protocol using FMT in cancer patients and I will announce once we’re site activated at the Orlando Health Cancer Institute. The revolutionary world of cancer treatment is once again on …
Intratumoral therapies is another class of immunotherapeutics that I often consider especially for folks with limited skin or nodal disease or perhaps deeper oligometastatic disease. I have cutaneous malignancies patients with Melanoma, Cutaneous SCC, Merkel cell and Kaposi sarcomas that have responded to local intratumoral therapies. We’ve seen viral agents like FDA approved TVEC, RP1, …